推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (warmed)
储存温度
2-8°C
SMILES字符串
C[C@]([H])(O[C@@]([H])(C1)C)CN1C2=CC(C3=NNC(C3=C4)=CC=C4OC5(C)CC5)=NC=N2
InChI key
ATUUNJCZCOMUKD-OKILXGFUSA-N
生化/生理作用
MLi-2 is an orally available, CNS active, highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. MLi-2 potently inhibits central and peripheral LRRK2 in mice.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
从最新的版本中选择一种：
分析证书(COA)
Lot/Batch Number
Lindsey M Crown et al.
Frontiers in neurology, 11, 324-324 (2020-06-02)
Sleep disturbances co-occur with and precede the onset of motor symptoms in Parkinson's disease (PD). We evaluated sleep fragmentation and thalamocortical sleep spindles in mice expressing the p.G2019S mutation of the leucine-rich repeat kinase 2 (LRRK2) gene, one of the
Reika Watanabe et al.
Cell, 182(6), 1508-1518 (2020-08-14)
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most frequent cause of familial Parkinson's disease. LRRK2 is a multi-domain protein containing a kinase and GTPase. Using correlative light and electron microscopy, in situ cryo-electron tomography, and subtomogram analysis, we
Matthew J Fell et al.
The Journal of pharmacology and experimental therapeutics, 355(3), 397-409 (2015-09-27)
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD). That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门